Assenagon Asset Management S.A. Purchases 129,363 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Assenagon Asset Management S.A. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,571,273 shares of the medical equipment provider’s stock after acquiring an additional 129,363 shares during the quarter. Intuitive Surgical comprises about 1.3% of Assenagon Asset Management S.A.’s portfolio, making the stock its 11th biggest holding. Assenagon Asset Management S.A. owned approximately 0.44% of Intuitive Surgical worth $820,142,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in ISRG. Hazlett Burt & Watson Inc. raised its position in Intuitive Surgical by 5.8% in the third quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider’s stock worth $177,000 after acquiring an additional 20 shares during the period. Mitchell Mcleod Pugh & Williams Inc. grew its stake in Intuitive Surgical by 4.1% in the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider’s stock worth $247,000 after buying an additional 20 shares in the last quarter. Fragasso Financial Advisors Inc boosted its holdings in shares of Intuitive Surgical by 3.0% in the 4th quarter. Fragasso Financial Advisors Inc now owns 687 shares of the medical equipment provider’s stock worth $359,000 after purchasing an additional 20 shares in the last quarter. Ullmann Wealth Partners Group LLC boosted its position in Intuitive Surgical by 1.6% during the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock valued at $653,000 after buying an additional 21 shares during the period. Finally, Meeder Advisory Services Inc. grew its position in Intuitive Surgical by 0.3% during the 3rd quarter. Meeder Advisory Services Inc. now owns 7,386 shares of the medical equipment provider’s stock worth $3,629,000 after acquiring an additional 22 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Mark Brosius sold 2,128 shares of the company’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,095,920.00. Following the completion of the transaction, the senior vice president now directly owns 273 shares in the company, valued at approximately $140,595. This represents a 88.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Gary S. Guthart sold 18,151 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the transaction, the chief executive officer now owns 24,219 shares in the company, valued at approximately $12,391,166.97. This trade represents a 42.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,190 shares of company stock valued at $25,012,927. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Trading Down 0.2 %

ISRG stock opened at $538.88 on Wednesday. The company has a market capitalization of $191.94 billion, a PE ratio of 86.64, a P/E/G ratio of 5.31 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $355.17 and a 12-month high of $556.23. The business’s fifty day moving average price is $537.05 and its 200 day moving average price is $496.50.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. The company had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. Research analysts predict that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on ISRG shares. Royal Bank of Canada raised their price target on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Friday, October 18th. Wells Fargo & Company boosted their target price on Intuitive Surgical from $549.00 to $630.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. BTIG Research raised their price target on shares of Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. JPMorgan Chase & Co. upped their target price on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Raymond James increased their price target on Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $554.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.